Asst. Prof. Ahmet Cingöz is a molecular cancer biologist whose research focuses on understanding the mechanisms of therapy resistance in aggressive cancers. His work combines genetic, epigenetic, and transcriptomic approaches to identify key drivers of treatment resistance and tumor survival. In triple-negative breast cancer, he discovered that the epigenetic reader protein BRPF1 regulates chemotherapy resistance by controlling ABCB1 expression and ribosome biogenesis. Targeting BRPF1, either genetically or with small-molecule inhibitors, restores sensitivity to Taxol, providing a potential avenue for overcoming multidrug resistance.
In addition to breast cancer, his research explores the molecular pathways that govern tumor cell apoptosis and response to targeted therapies. He has characterized pro-apoptotic proteins such as HRK and studied adaptive resistance mechanisms to pro-apoptotic agents like TRAIL. These investigations revealed critical roles for signaling pathways, including NF-κB, and highlighted combination strategies to re-sensitize resistant cancer cells. Together, his studies provide insight into tumor survival mechanisms and inform the development of novel therapeutic strategies against treatment-resistant cancers.
Click here for the Avasis link
